Docetaxel intratumoural - LIDDS

Drug Profile

Docetaxel intratumoural - LIDDS

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LIDDS
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Non-small cell lung cancer

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 31 Aug 2017 LIDDS plans a phase I trial for Solid tumours in 2018
  • 30 Jun 2017 Docetaxel intratumoural - LIDDS is available for licensing following phase I development as of 30 Jun 2017 . http://www.liddspharma.com
  • 30 Jun 2017 LIDDS has patent protection for its NanoZolid® technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top